These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Exemestane for primary prevention of breast cancer in postmenopausal women. Zhang Y, Simondsen K, Kolesar JM. Am J Health Syst Pharm; 2012 Aug 15; 69(16):1384-8. PubMed ID: 22855103 [Abstract] [Full Text] [Related]
11. Use of SERMs for treatment in postmenopausal women. Pinkerton JV, Thomas S. J Steroid Biochem Mol Biol; 2014 Jul 15; 142():142-54. PubMed ID: 24373794 [Abstract] [Full Text] [Related]
12. Raloxifene: A selective estrogen receptor modulator (SERM) with multiple target system effects. Muchmore DB. Oncologist; 2000 Jul 15; 5(5):388-92. PubMed ID: 11040275 [Abstract] [Full Text] [Related]
18. [What can we expect of raloxifene in the treatment of postmenopausal osteoporosis--views of a gynecologist]. Chmel R, Rob L, Strnad P. Ceska Gynekol; 2002 Jul 16; 67(4):187-91. PubMed ID: 12373918 [Abstract] [Full Text] [Related]
19. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER, Wade JL, Robidoux A, Margolese RG, James J, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N, National Surgical Adjuvant Breast and Bowel Project. Cancer Prev Res (Phila); 2010 Jun 16; 3(6):696-706. PubMed ID: 20404000 [Abstract] [Full Text] [Related]
20. The role of selective estrogen receptor modulators (SERMs) in postmenopausal health. Draper MW. Ann N Y Acad Sci; 2003 Nov 16; 997():373-7. PubMed ID: 14644844 [Abstract] [Full Text] [Related] Page: [Next] [New Search]